Prot #CA0881000: A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Project: Research project

Project Details

StatusActive
Effective start/end date10/11/24 → 10/11/27

Funding

  • Juno Therapeutics, Inc. (Prot #CA0881000)